← Back to Search

Other

FOR46 for Multiple Myeloma

Phase 1
Waitlist Available
Research Sponsored by Fortis Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Disease response
Incidence of adverse events
Occurrence of dose-limiting toxicities
Secondary outcome measures
Antidrug Antibodies
Characterize FOR46 elimination
Plasma
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Experimental: FOR46 (Dose Expansion)Experimental Treatment1 Intervention
Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
Group II: Experimental: FOR46 (Dose Escalation)Experimental Treatment1 Intervention
Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FOR46
2019
Completed Phase 1
~90

Find a Location

Who is running the clinical trial?

Fortis Therapeutics, Inc.Lead Sponsor
3 Previous Clinical Trials
116 Total Patients Enrolled
Andrew Dorr, MDStudy DirectorFortis Therapeutics, Inc.
1 Previous Clinical Trials
56 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
2019. "A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03650491.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top